Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2026Infectious Diseases and TherapyOpen Access

Long‑Term Effectiveness and Safety of Doravirine‑Based Antiretroviral Regimens in Virologically Suppressed People with HIV: The French Dat’AIDS Cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

CAClotilde AllavenaSFSean P. FlemingCDColin Deschanvres

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates sustained virologic suppression and favorable safety with doravirine regimens in virologically suppressed HIV, supporting doravirine as a durable switch strategy.

Key Points

  • To evaluate the long-term effectiveness, safety, and treatment durability of doravirine-based antiretroviral regimens following a treatment switch in virologically suppressed adults with HIV.
  • Analyzed data from 1,666 treatment-experienced adults with confirmed HIV-1 RNA < 50 copies/ml initiating a doravirine-based regimen between April 2019 and June 2024 (NCT02898987).
  • Monitored virologic suppression, reasons for treatment discontinuation, body weight, lipid parameters, and organ function until doravirine discontinuation, death, or December 2024.
  • Virologic suppression was maintained in 97% of individuals at 12 months and 96% at 48 months following treatment switch.
  • Treatment discontinuation occurred in 45 individuals, with 11 discontinuing due to adverse events and 2 due to virologic failure, with zero cases of emergent antiretroviral resistance.
  • Follow-up revealed only small changes in body weight, lipid profiles, and renal or hepatic function markers.

Cite This Study

Allavena et al. (2026) studied this question.

synapsesocial.com/papers/6a895eaeca7ade938187cb76https://doi.org/10.1007/s40121-026-01422-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment durability, satisfaction and quality of life in virologically suppressed <scp>HIV</scp> ‐1 people switching to doravirine: Results from the French study <scp>DoraVIH</scp>2026
  2. 2Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life2024 · 6 citations
  3. 3Profile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Study2026
  4. 4P-347. Clinical outcomes of heavily treatment-experienced people living with multidrug resistant HIV switched to a doravirine vs. non-doravirine containing regimen2026
  5. 5Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV2026